Senate panel hits Sanofi payments
Sanofi SA contributed more than $5 million to two medical groups and a medical researcher that encouraged U.S. regulators to delay approval of a drug that would undercut the company's blockbuster blood-thinner Lovenox, according to a new report from the Senate Finance Committee. Letters to the FDA from the groups--the Society of Hospital Medicine and the North American Thrombosis Forum—and the researcher, Victor Tapson, a thrombosis expert at Duke University, said that generic versions of Lovenox, a fast-acting anticlotting medicine, might not be as safe as the brand-name drug, according to the report. The letters didn't mention financial ties to Sanofi.
- Interventional Radiology No Longer a Sub-Specialty
- NFP Hospitals' Revenue Growth at 'All-Time Low'
- Acute Kidney Injury Gets New Focus
- Transforming Cancer Care
- Half of All Primary Care, Internal Medicine Jobs Unfilled in 2013
- Evidence-Based Practice and Nursing Research: Avoiding Confusion
- mHealth Tackles Readmissions
- CNO Leads $1M Charge for New Scrubs, Uniforms
- Sharp HealthCare Leaves Pioneer ACO Program
- MA an Insurance Proving Ground for Providers